Skip to main content

DESKi

Category: AI in Healthcare

HeartFocus is an FDA-cleared, AI-powered cardiac ultrasound tool that enables any healthcare professional to capture and interpret diagnostic-quality heart scans at the point of care. DESKi was founded in 2016. The company is led by Dr. Bertrand Moal. Based in Bordeaux, France. Team size: 11-50. Total funding raised: $6 million. Latest round: Seed. Key investors include Racine², Serena, Makesense, BNP Paribas Développement, Épopée Gestion, Good Only Ventures, Better Angle, NACO.

Founded
2016
Headquarters
Bordeaux, France
Team size
11-50
Total funding
$6 million

Value proposition

Democratizes access to cardiac ultrasound by empowering non-specialist healthcare professionals to perform and interpret exams, enabling earlier detection of heart disease.

Products and solutions

HeartFocus

Unique value

Focus on usability for non-specialists. The AI guides the user to capture the correct image and provides an automated interpretation, lowering the barrier to using ultrasound for cardiac diagnostics.

Target customer

Hospitals, clinics, and various points of care (e.g., primary care, emergency departments) where immediate cardiac assessment is needed.

Industries served

Healthcare, Medical Devices

Technology advantage

Proprietary AI for image acquisition guidance and interpretation. Received FDA clearance with a Predetermined Change Control Plan (PCCP), enabling more efficient future updates and model improvements.

How they differentiate

Unlike competitors who often focus on analysis for expert cardiologists, DESKi's HeartFocus is designed to assist non-specialists in both capturing and interpreting images, aiming to expand ultrasound use to new points of care.

Main competitors

Caption Health (GE Healthcare), Ultromics, Eko Health, Kosmos by EchoNous

Key partnerships

APHP (Greater Paris University Hospitals), Butterfly Network (US commercial launch partner, Aug 2025), Various US and European app platform and SDK providers

Notable customers

APHP (Greater Paris University Hospitals) is a key research partner. Butterfly Network is a commercial launch partner (Aug 2025). Commercial end-customers not yet publicly disclosed.

Major milestones

Founded in 2016. Received FDA clearance for HeartFocus software in April 2025. Secured a $6 million seed funding round led by Racine² in June 2025. Awarded the France 2030 Award by the French Ministry of Health in 2024. Launched first US clinical product with Butterfly Network in August 2025.

Growth metrics

Secured FDA clearance, which is a primary catalyst for market entry and growth. User adoption and partnership metrics are not yet public.

Market positioning

An early-stage HealthTech company poised for commercial growth, focusing on deploying its FDA-cleared point-of-care ultrasound guidance and analysis software.

Geographic focus

Initially U.S. (leveraging FDA clearance), with a global expansion strategy for Europe and other markets.

Patents and IP

Information not publicly available.

About Dr. Bertrand Moal

Dr. Bertrand Moal is a medical doctor with a Ph.D. in Biomechanics. He is the co-founder and CEO of DESKi, a company that develops AI-powered cardiac ultrasound tools. He has experience in both the medical and business fields, and is passionate about using technology to improve healthcare.

Official website: